Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.45 |
| ▸ | BCR | P11274 | 4/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 12/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 4/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | SGK1 | O00141 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24137540 | 0.74 | JAK2 (0.58) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL25935940 | 0.74 | GSK3B (0.46) | JAK2GSK3B | |
| SCHEMBL25933239 | 0.70 | ABL1 (0.54) | ABL1BCRJAK2PDPK1AURKA | |
| SCHEMBL24137787 | 0.69 | JAK2 (0.61) | JAK2PDPK1GSK3BAURKATGFBR1 | |
| SCHEMBL6478095 | 0.69 | JAK2 (0.59) | ABL1BCRJAK2PDPK1GSK3B | |
| SCHEMBL6480460 | 0.68 | PDPK1 (0.65) | JAK2PDPK1GSK3BAURKATGFBR1 | |
| SCHEMBL24137502 | 0.68 | JAK2 (0.48) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL24137503 | 0.68 | MAP2K4 (0.55) | ABL1BCRJAK2PDPK1AURKA | |
| SCHEMBL24137497 | 0.67 | MAP2K4 (0.54) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL25933236 | 0.67 | PDPK1 (0.49) | ABL1BCRJAK2PDPK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | ABL1 326/4885BCR 3288/4885JAK2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.